A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease

Int J Chron Obstruct Pulmon Dis. 2014 Jul 18:9:775-83. doi: 10.2147/COPD.S64491. eCollection 2014.

Abstract

Objective: To compare clinical and demographic characteristics, resource utilization and costs of chronic obstructive pulmonary disease (COPD) patients prior to initiating budesonide-formoterol combination (BFC) or tiotropium-maintenance therapy.

Materials and methods: This cross-sectional study used claims-based diagnosis to identify COPD patients in the HealthCore Integrated Research Database who initiated BFC or tiotropium therapy between March 1, 2009 and January 31, 2012 (intake period); the index date was defined as the initial prescription fill for either agent. Patients diagnosed with respiratory tract cancer or receiving inhaled corticosteroids/long-acting β2-adrenergic agonists or tiotropium in 12 months prior to index date were excluded. Categorical variables were evaluated with χ(2) tests; mean cost differences were evaluated using γ-regression.

Results: Overall, 6,940 BFC and 10,831 tiotropium patients were identified. The BFC group was younger (mean age 64 versus 67 years), with a greater proportion of females (54% versus 51%). BFC-treated patients had more comorbid respiratory conditions, including asthma (25% versus 13%), but fewer comorbid cardiovascular conditions, including atherosclerosis (7% versus 10%) and myocardial infarction (4% versus 6%). A greater proportion of BFC patients received prior respiratory medication, including oral corticosteroids (46% versus 35%) and short-acting β2-agonists (44% versus 35%). Tiotropium-treated patients had a greater mean number of COPD-related outpatient visits (4.6 versus 4.1). BFC-treated patients had lower total all-cause ($17,259 versus $17,926) and COPD-related ($1,718 versus $1,930) health care costs, driven by lower all-cause and COPD-related inpatient expenditures.

Conclusion: Initiators of BFC or tiotropium showed differences in clinical and demographic characteristics and health care utilization and costs prior to starting COPD maintenance therapy.

Keywords: chronic respiratory condition; health care utilization and costs; observational study; outcome research; retrospective analysis.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-2 Receptor Agonists / adverse effects
  • Adrenergic beta-2 Receptor Agonists / economics
  • Adrenergic beta-2 Receptor Agonists / therapeutic use*
  • Adult
  • Age Factors
  • Aged
  • Bronchodilator Agents / adverse effects
  • Bronchodilator Agents / economics
  • Bronchodilator Agents / therapeutic use*
  • Budesonide / adverse effects
  • Budesonide / economics
  • Budesonide / therapeutic use*
  • Chi-Square Distribution
  • Cholinergic Antagonists / adverse effects
  • Cholinergic Antagonists / economics
  • Cholinergic Antagonists / therapeutic use*
  • Comorbidity
  • Cross-Sectional Studies
  • Data Mining
  • Databases, Factual*
  • Drug Combinations
  • Drug Costs
  • Ethanolamines / adverse effects
  • Ethanolamines / economics
  • Ethanolamines / therapeutic use*
  • Female
  • Formoterol Fumarate
  • Glucocorticoids / adverse effects
  • Glucocorticoids / economics
  • Glucocorticoids / therapeutic use*
  • Health Expenditures
  • Humans
  • Male
  • Middle Aged
  • Odds Ratio
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / drug therapy*
  • Pulmonary Disease, Chronic Obstructive / economics
  • Pulmonary Disease, Chronic Obstructive / epidemiology
  • Pulmonary Disease, Chronic Obstructive / physiopathology
  • Scopolamine Derivatives / adverse effects
  • Scopolamine Derivatives / economics
  • Scopolamine Derivatives / therapeutic use*
  • Sex Factors
  • Time Factors
  • Tiotropium Bromide
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Bronchodilator Agents
  • Cholinergic Antagonists
  • Drug Combinations
  • Ethanolamines
  • Glucocorticoids
  • Scopolamine Derivatives
  • Budesonide
  • Formoterol Fumarate
  • Tiotropium Bromide